Standardized evaluation of therapeutic efficacy based on cellular biomarkers

• US 20040171091A1
• Filed: 02/27/2004
• Published: 09/02/2004
• Est. Priority Date: 02/27/2003
• Status: Abandoned Application

• Current Assignee: CELLective Dx Corporation
• Original Assignee: Cell Works, Inc.
• Inventors: Tsʼo, Paul O.P., Lesko, Stephen A.
• Application Number:
  US10/787,585
• Publication Number:
  US 20040171091A1
• Time in Patent Office: Days
• US Class Current: 435/7.23
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism

Abstract

The present invention provides materials and methods for predicting the response of a disease state to a therapeutic agent. A targeting moiety specific for a biological marker is labeled with a reporter moiety and used to analyze cells characteristic of the disease state. The output of the reporter moiety, which may be fluorescence intensity, is compared to the output of reference standard analyzed under similar or identical conditions. The use of a reference standard allows biomarker reporting to be normalized. Biomarker values can then be correlated from sample to sample and from laboratory to laboratory based on quantitative calibration on a universal reference standard.

Claims

1. A method of selecting a therapeutic agent for treatment of a disease state in a patient, comprising:

obtaining a cell sample from the patient, wherein the sample comprises cells characteristic of the disease state and the cells comprise one or more biomarkers;

contacting the cells with a test compound that specifically binds to one or more biomarkers and comprises a fluorescent moiety;

measuring the intensity of the fluorescence of the cells; and

comparing the intensity of the fluorescence of the cells to a fluorescence intensity of a reference standard, wherein the ratio of the intensities correlates to the effectiveness of the therapeutic agent against the disease state.

2. The method of claim 1, further comprising calculating the ratio of the fluorescence intensity of the cells to the fluorescence intensity of the reference standard.

3. The method of claim 1, wherein said sample is obtained from a body fluid using a negative selection.

4. The method of claim 3, wherein the body fluid is blood.

5. The method of claim 4, wherein the disease state is cancer.

6. The method of claim 1, wherein the patient is in need a cancer therapy.

7. A method of selecting a therapeutic agent for the treatment of cancer, comprising:

obtaining a cell sample from a patient, wherein the sample comprises circulating cancer cells and said cancer cells comprise one or more biomarkers;

contacting the cells with a test compound that specifically binds to one or more biomarkers and comprises a fluorescent moiety;

measuring the intensity of the fluorescence of the cells; and

comparing the intensity of the fluorescence of the cells to that of a reference standard, wherein the ratio of the intensities correlates to the effectiveness of the therapeutic agent against the cancer.

8. The method of claim 7, wherein the test compound is a therapeutic agent coupled to a reporter moiety.

9. The method of claim 8, wherein the therapeutic agent is selected from a group consisting of Erbitux, Herceptin®

, and Avastin™

.

10. The method of claim 8, wherein the therapeutic agent is Herceptin®

.

11. The method of claim 8, wherein the therapeutic agent comprises a monoclonal antibody.

12. The method of claim 7, wherein the test compound comprises a targeting moiety that interacts with a biomarker indicative of sensitivity to a therapeutic agent selected from the group consisting of Gemcitabine, Cisplatinum, Paclitaxel (Taxol), Vinorelbine (Vinca Alkaloid), 5 FU-related drugs, and Iressa.

13. The method of claim 7, wherein the reference standard is a fluorescent microsphere.

14. A kit for determining the susceptibility of a cancer cell to a therapeutic agent, comprising a targeting moiety coupled to a fluorescent moiety.

15. The kit according to claim 14, wherein the targeting moiety comprises the therapeutic agent.

16. The kit according to claim 15, wherein the therapeutic agent comprises one or more antibodies.

17. The kit according to claim 16, wherein at least one antibody is a monoclonal antibody.

18. The kit according to claim 14, further comprising at least one antibody specific for a cytokeratin.

19. The kit according to claim 18, wherein at least one antibody comprises a fluorescent moiety.

20. The kit according to claim 18, wherein at least one antibody specific for a cytokeratin is a monoclonal antibody.

21. The kit according to claim 14, further comprising a reference standard.

22. The kit according to claim 21, wherein the reference standard is fluorescent.

23. The kit according to claim 22, wherein the calibration reagent is a fluorescent microsphere.